We rank companies based on fund manager, research analyst and news sentiment
ADPT stock icon

Adaptive Biotechnologies
ADPT

$2.33
4.3%
 

About: Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Employees: 709

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 5 analysts
0
News positive %
of 4 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

24% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 29

4% more funds holding

Funds holding: 187 [Q3] → 194 (+7) [Q4]

2.11% more ownership

Funds ownership: 97.06% [Q3] → 99.17% (+2.11%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

8% less capital invested

Capital invested by funds: $765M [Q3] → $704M (-$61.2M) [Q4]

18% less repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 71

43% less call options, than puts

Call options by funds: $282K | Put options by funds: $491K

Research analyst outlook

5 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$5
114%
upside
Avg. target
$6.8
191%
upside
High target
$10
328%
upside

5 analyst ratings

positive
60%
neutral
40%
negative
0%
BTIG
Mark Massaro
114%upside
$5
Buy
Maintained
4 Apr 2024
Goldman Sachs
Salveen Richter
114%upside
$5
Neutral
Maintained
16 Feb 2024
JP Morgan
Rachel Vatnsdal
243%upside
$8
Overweight
Maintained
15 Feb 2024
Piper Sandler
David Westenberg
157%upside
$6
Overweight
Maintained
13 Nov 2023
Morgan Stanley
Tejas Savant
328%upside
$10
Equal-Weight
Maintained
24 Oct 2023

Financial journalist opinion

Based on 4 articles about ADPT published over the past 30 days